BiotechTube
Home/Pipeline/Parkin Activator Program

Parkin Activator Program

Parkinson's Disease

Pre-clinicalActive

Key Facts

Indication
Parkinson's Disease
Phase
Pre-clinical
Status
Active
Company
Progenra

About Progenra

Progenra is a private, preclinical-stage biotech founded in 2002, headquartered in Malvern, Pennsylvania. The company is a leader in the targeted protein degradation (TPD) space, utilizing its UbiPro™ platform to discover molecular glues and PROTACs aimed at previously 'undruggable' targets. With a focus on neurodegenerative diseases like Parkinson's, and backed by non-dilutive funding such as grants from The Michael J. Fox Foundation, Progenra is advancing a pipeline of first-in-class therapeutics. The company is led by founder and CEO Dr. Tauseef R. Butt, who has a strong track record in UPS research and capital formation.

View full company profile

Therapeutic Areas

Neurodegenerative DiseasesCardiovascular DisordersMetabolic DysfunctionAging & Cellular Longevity

Other Parkinson's Disease Drugs

DrugCompanyPhase
NPT200-11Neuropore TherapiesPhase 1
NUZ-001Neurizon TherapeuticsPreclinical
VXX-301VaxxinityPreclinical
BAN2802BioArcticPhase 1
CNM-Au8ClenePhase 2
hpSC-Derived Neural/Dopaminergic CellsInternational Stem CellPreclinical/Early Clinical
SLS-004Seelos TherapeuticsPreclinical
SLS-007Seelos TherapeuticsPreclinical
Parkinson's Disease Portfolio (Platform-derived)WD PharmaceuticalNot Disclosed (Likely Preclinical/Early Clinical)
UX-DA001UniXellPhase 1
Parkinson's Disease ResearchProgenaBiomeResearch
A9 Dopaminergic Neuron TherapyTrailhead BiosystemsPre-clinical